Compare FCT & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCT | PROF |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.1M | 230.4M |
| IPO Year | N/A | N/A |
| Metric | FCT | PROF |
|---|---|---|
| Price | $10.09 | $7.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 106.8K | ★ 240.4K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 11.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,297,000.00 |
| Revenue This Year | N/A | $64.23 |
| Revenue Next Year | N/A | $113.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.94 |
| 52 Week Low | $9.45 | $3.76 |
| 52 Week High | $10.42 | $8.95 |
| Indicator | FCT | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 59.29 | 45.16 |
| Support Level | $9.95 | $7.40 |
| Resistance Level | $10.11 | $8.15 |
| Average True Range (ATR) | 0.04 | 0.55 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 78.13 | 9.39 |
First Trust Senior Floating Rate Income Fund II is a United States-based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, it attempts to preserve capital. The fund invests in a portfolio of senior secured floating-rate corporate loans (Senior Loans) of companies from different industries, such as Insurance, Software, Health Care Providers and Services, Professional Services, Health Care Technology, IT Services, and others.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.